Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 335

1.

Pharmacological Treatment of Major Depressive Episodes with Mixed Features: A Systematic Review.

Shim IH, Bahk WM, Woo YS, Yoon BH.

Clin Psychopharmacol Neurosci. 2018 Nov 30;16(4):376-382. doi: 10.9758/cpn.2018.16.4.376. Review.

2.

Treatment for Bipolar Disorder in Adults: A Systematic Review [Internet].

Butler M, Urosevic S, Desai P, Sponheim SR, Popp J, Nelson VA, Thao V, Sunderlin B.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Aug.

3.

A Focused Review on the Treatment of Pediatric Patients with Atypical Antipsychotics.

Lee ES, Vidal C, Findling RL.

J Child Adolesc Psychopharmacol. 2018 Nov;28(9):582-605. doi: 10.1089/cap.2018.0037. Epub 2018 Oct 12.

PMID:
30312108
4.

A History of the Pharmacological Treatment of Bipolar Disorder.

López-Muñoz F, Shen WW, D'Ocon P, Romero A, Álamo C.

Int J Mol Sci. 2018 Jul 23;19(7). pii: E2143. doi: 10.3390/ijms19072143. Review.

5.
6.

Comprehensive comparison of monotherapies for psychiatric hospitalization risk in bipolar disorders.

Nestsiarovich A, Mazurie AJ, Hurwitz NG, Kerner B, Nelson SJ, Crisanti AS, Tohen M, Krall RL, Perkins DJ, Lambert CG.

Bipolar Disord. 2018 Jun 19. doi: 10.1111/bdi.12665. [Epub ahead of print]

PMID:
29920885
7.

Mixed states in bipolar and major depressive disorders: systematic review and quality appraisal of guidelines.

Verdolini N, Hidalgo-Mazzei D, Murru A, Pacchiarotti I, Samalin L, Young AH, Vieta E, Carvalho AF.

Acta Psychiatr Scand. 2018 Sep;138(3):196-222. doi: 10.1111/acps.12896. Epub 2018 May 13. Review.

PMID:
29756288
8.

Medications Used for Cognitive Enhancement in Patients With Schizophrenia, Bipolar Disorder, Alzheimer's Disease, and Parkinson's Disease.

Hsu WY, Lane HY, Lin CH.

Front Psychiatry. 2018 Apr 4;9:91. doi: 10.3389/fpsyt.2018.00091. eCollection 2018. Review.

9.

Hospitalization risk in bipolar disorder patients treated with lurasidone versus other atypical antipsychotics.

Ng-Mak D, Halpern R, Rajagopalan K, Loebel A.

Curr Med Res Opin. 2018 Apr 22:1-9. doi: 10.1080/03007995.2018.1462787. [Epub ahead of print]

PMID:
29625538
10.

Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.

Temmingh HS, Williams T, Siegfried N, Stein DJ.

Cochrane Database Syst Rev. 2018 Jan 22;1:CD011057. doi: 10.1002/14651858.CD011057.pub2. Review.

PMID:
29355909
11.

Clozapine use in patients with schizophrenia and a comorbid substance use disorder: A systematic review.

Arranz B, Garriga M, García-Rizo C, San L.

Eur Neuropsychopharmacol. 2018 Feb;28(2):227-242. doi: 10.1016/j.euroneuro.2017.12.006. Epub 2017 Dec 19. Review.

PMID:
29273271
12.

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long-term treatment of mixed states in bipolar disorder.

Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Azorin JM, Yatham L, Mosolov S, Möller HJ, Kasper S; Members of the WFSBP Task Force on Bipolar Affective Disorders Working on this topic.

World J Biol Psychiatry. 2018 Feb;19(1):2-58. doi: 10.1080/15622975.2017.1384850. Epub 2017 Nov 3. Review.

PMID:
29098925
13.

Weight changes before and after lurasidone treatment: a real-world analysis using electronic health records.

Meyer JM, Ng-Mak DS, Chuang CC, Rajagopalan K, Loebel A.

Ann Gen Psychiatry. 2017 Oct 17;16:36. doi: 10.1186/s12991-017-0159-x. eCollection 2017.

14.

Ziprasidone.

Bouchette D, Pellegrini MV.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.
2018 Dec 2.

15.

Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.

Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, Stubbs B, Monaco F, Vieta E, Seeman MV, Correll CU, Carvalho AF.

Ther Clin Risk Manag. 2017 Jun 29;13:757-777. doi: 10.2147/TCRM.S117321. eCollection 2017. Review.

16.

Elevated levels of AST, ALT, and CPK · no family history of liver disease · Dx?

Patel MB, Maddur H.

J Fam Pract. 2017 Jul;66(7):450-452.

PMID:
28700759
17.

Patient Characteristics Associated With Use of Lurasidone Versus Other Atypical Antipsychotics in Patients With Bipolar Disorder: Analysis From a Claims Database in the United States.

Tohen M, Ng-Mak D, Rajagopalan K, Halpern R, Chuang CC, Loebel A.

Prim Care Companion CNS Disord. 2017 Jun 1;19(3). doi: 10.4088/PCC.16m02066.

18.

A Retrospective Cohort Study of Acute Kidney Injury Risk Associated with Antipsychotics.

Jiang Y, McCombs JS, Park SH.

CNS Drugs. 2017 Apr;31(4):319-326. doi: 10.1007/s40263-017-0421-4.

PMID:
28290080
19.

Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: A systematic review and network meta-analysis.

Ostacher M, Ng-Mak D, Patel P, Ntais D, Schlueter M, Loebel A.

World J Biol Psychiatry. 2017 Mar 7:1-11. doi: 10.1080/15622975.2017.1285050. [Epub ahead of print]

PMID:
28264635
20.

Maintenance therapy with second generation antipsychotics for bipolar disorder - A systematic review and meta-analysis.

Lindström L, Lindström E, Nilsson M, Höistad M.

J Affect Disord. 2017 Apr 15;213:138-150. doi: 10.1016/j.jad.2017.02.012. Epub 2017 Feb 14. Review.

PMID:
28222360

Supplemental Content

Loading ...
Support Center